Benefit of Daratumumab Across Populations With Newly Diagnosed Multiple Myeloma

This week, we review a presentation on the benefit of daratumumab across populations with newly diagnosed multiple myeloma. We also talk about a study on racial disparities in colorectal cancer mortality. Lastly, we discuss the U.S. Food and Drug Administration’s recent approval of apalutamide in metastatic castration-sensitive prostate cancer.

---